Amgen’s trebananib hits main goal in ovarian cancer trial

Amgen's experimental drug trebananib, or AMG 386, in combination with paclitaxel, achieved the primary goal of a late-stage s -More- …

---

Amgen, Cytokinetics expand collaboration

Amgen and Cytokinetics, a clinical-stage biopharmaceutical company, have expanded their strategic collaboration to include Japan. In 2006, Cytokinetics and Amgen entered into a collaboration to d…

---

Amgen’s trebananib succeeds in PhIII for ovarian cancer

Amgen's trebananib succeeds in PhIII for ovarian cancer…

---

Amgen says drug slowed ovarian cancer in trial

(Reuters) - Amgen Inc's trebananib drug for ovarian cancer extended the length of time that patients lived without the disease getting worse by about two months, meeting the main goal of a late-stage…

---